Answers are grounded in this paper and cite their sources.
In a three week double-blind cross-over controlled trial in twenty asthmatic children, ketotifen (HC 20-511, 'Zaditen', Sandoz) showed no significant difference from placebo, although there was a consistent trend in favour of the active drug.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: